Acutus Medical Inc (OTCPK:AFIB)

$ 0.0602 0 (0%) Market Cap: 1.80 Mil Enterprise Value: 24.99 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Q2 2023 Acutus Medical Inc Earnings Call Transcript
Aug 07, 2023

$0.676 (-2.03%)

Earnings
Q1 2023 Acutus Medical Inc Earnings Call Transcript
May 11, 2023

$0.9494 (-1.12%)

Earnings
Acutus Medical Inc To Discuss Results From RECOVER AF Study Transcript
Apr 21, 2023
Q4 2022 Acutus Medical Inc Earnings Call Transcript
Mar 16, 2023

$1 (+11.11%)

Earnings
Q3 2022 Acutus Medical Inc Earnings Call Transcript
Nov 10, 2022

$0.7521 (-1.05%)

Earnings
Q2 2022 Acutus Medical Inc Earnings Call Transcript
Aug 11, 2022

$1.66 (+3.11%)

Earnings
Q1 2022 Acutus Medical Inc Earnings Call Transcript
May 12, 2022

$0.94 (+5.00%)

Earnings
Acutus Medical Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
Q4 2021 Acutus Medical Inc Earnings Call Transcript
Mar 30, 2022

$1.93 (+1.58%)

Earnings
Q3 2021 Acutus Medical Inc Earnings Call Transcript
Nov 11, 2021

$6.66 (-9.88%)

Earnings
Q2 2021 Acutus Medical Inc Earnings Call Transcript
Aug 12, 2021

$13.29 (-7.77%)

Earnings
Acutus Medical Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021
Q1 2021 Acutus Medical Inc Earnings Call Transcript
May 12, 2021

$11.59 (-2.77%)

Earnings
Q4 2020 Acutus Medical Inc Earnings Call Transcript
Mar 18, 2021

$16.83 (-11.70%)

Earnings
Acutus Medical Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Q3 2020 Acutus Medical Inc Earnings Call Transcript
Nov 12, 2020

$24.61 (+1.07%)

Earnings
Q2 2020 Acutus Medical Inc Earnings Call Transcript
Sep 17, 2020

$34.51 (-2.68%)

Earnings

Acutus Medical Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 03:00PM GMT

Release Date Price: $28.51 (-16.16%)

Transcript 8-K

Robert Justin Marcus

JPMorgan Chase & Co, Research Division - Analyst

Good morning, everyone. Happy to kick off the medtech track on the third day of the JPMorgan Healthcare Conference. I'm the medtech analyst here, Robbie Marcus, and I'm very happy to introduce Vince Burgess, the CEO of Acutus.

Before we jump into it, I just want to remind everyone, they could go to the conference website and find the slide deck there to follow along. (Operator Instructions)

So with that, Vince, I'll let you get to it.

Vincent J. Burgess

Acutus Medical, Inc. - President, CEO & Director

Great. Thank you, Robbie. I appreciate the time this morning, and I appreciate the invitation to present at JPMorgan. This is our first time presenting to JPMorgan. The company went public in August of last year, and I'm really excited to be here. So Kinsey, if you can bring up the first slide. Great. Thank you.

So really excited to present Acutus medical to you this morning. 2020 was just an amazing year for this company. In addition to our IPO, we made

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.